project id: TCGA-BLCA; case submitter id: TCGA-FD-A3NA; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.74; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.6; rna integrity number: 7.8; age at index: 60; days to birth: -21936; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 21936; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1845.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2009; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 2.4657534246575343; pack years smoked: 45.0; is ffpe: false; composition: Not Reported; days to collection: 997; days to sample procurement: 0; initial weight: 320.0; portion submitter id: TCGA-FD-A3NA-01A-11; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 2.0; percent necrosis: 0.0; percent neutrophil infiltration: 2.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;